Cargando…
Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727148/ https://www.ncbi.nlm.nih.gov/pubmed/36323881 http://dx.doi.org/10.1038/s41416-022-02043-7 |
| _version_ | 1784844944718954496 |
|---|---|
| author | Qin, Shukui Li, Jin Zhong, Haijun Jin, Chuan Chen, Lili Yuan, Xianglin Fan, Qingxia Chen, Kehe Cao, Peiguo Xiao, Jianjun Jiang, Da Zhang, Tao Zhang, Hongyu Wang, Xicheng Wang, Wei Han, Lin Wang, Qingyu Zhu, Jun |
| author_facet | Qin, Shukui Li, Jin Zhong, Haijun Jin, Chuan Chen, Lili Yuan, Xianglin Fan, Qingxia Chen, Kehe Cao, Peiguo Xiao, Jianjun Jiang, Da Zhang, Tao Zhang, Hongyu Wang, Xicheng Wang, Wei Han, Lin Wang, Qingyu Zhu, Jun |
| author_sort | Qin, Shukui |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9727148 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97271482022-12-08 Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial Qin, Shukui Li, Jin Zhong, Haijun Jin, Chuan Chen, Lili Yuan, Xianglin Fan, Qingxia Chen, Kehe Cao, Peiguo Xiao, Jianjun Jiang, Da Zhang, Tao Zhang, Hongyu Wang, Xicheng Wang, Wei Han, Lin Wang, Qingyu Zhu, Jun Br J Cancer Correction Nature Publishing Group UK 2022-11-02 2022-12-07 /pmc/articles/PMC9727148/ /pubmed/36323881 http://dx.doi.org/10.1038/s41416-022-02043-7 Text en © The Author(s), under exclusive licence to Springer Nature Limited 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Qin, Shukui Li, Jin Zhong, Haijun Jin, Chuan Chen, Lili Yuan, Xianglin Fan, Qingxia Chen, Kehe Cao, Peiguo Xiao, Jianjun Jiang, Da Zhang, Tao Zhang, Hongyu Wang, Xicheng Wang, Wei Han, Lin Wang, Qingyu Zhu, Jun Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial |
| title | Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial |
| title_full | Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial |
| title_fullStr | Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial |
| title_full_unstemmed | Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial |
| title_short | Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial |
| title_sort | correction to: serplulimab, a novel anti-pd-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase ii trial |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727148/ https://www.ncbi.nlm.nih.gov/pubmed/36323881 http://dx.doi.org/10.1038/s41416-022-02043-7 |
| work_keys_str_mv | AT qinshukui correctiontoserplulimabanovelantipd1antibodyinpatientswithmicrosatelliteinstabilityhighsolidtumoursanopenlabelsinglearmmulticentrephaseiitrial AT lijin correctiontoserplulimabanovelantipd1antibodyinpatientswithmicrosatelliteinstabilityhighsolidtumoursanopenlabelsinglearmmulticentrephaseiitrial AT zhonghaijun correctiontoserplulimabanovelantipd1antibodyinpatientswithmicrosatelliteinstabilityhighsolidtumoursanopenlabelsinglearmmulticentrephaseiitrial AT jinchuan correctiontoserplulimabanovelantipd1antibodyinpatientswithmicrosatelliteinstabilityhighsolidtumoursanopenlabelsinglearmmulticentrephaseiitrial AT chenlili correctiontoserplulimabanovelantipd1antibodyinpatientswithmicrosatelliteinstabilityhighsolidtumoursanopenlabelsinglearmmulticentrephaseiitrial AT yuanxianglin correctiontoserplulimabanovelantipd1antibodyinpatientswithmicrosatelliteinstabilityhighsolidtumoursanopenlabelsinglearmmulticentrephaseiitrial AT fanqingxia correctiontoserplulimabanovelantipd1antibodyinpatientswithmicrosatelliteinstabilityhighsolidtumoursanopenlabelsinglearmmulticentrephaseiitrial AT chenkehe correctiontoserplulimabanovelantipd1antibodyinpatientswithmicrosatelliteinstabilityhighsolidtumoursanopenlabelsinglearmmulticentrephaseiitrial AT caopeiguo correctiontoserplulimabanovelantipd1antibodyinpatientswithmicrosatelliteinstabilityhighsolidtumoursanopenlabelsinglearmmulticentrephaseiitrial AT xiaojianjun correctiontoserplulimabanovelantipd1antibodyinpatientswithmicrosatelliteinstabilityhighsolidtumoursanopenlabelsinglearmmulticentrephaseiitrial AT jiangda correctiontoserplulimabanovelantipd1antibodyinpatientswithmicrosatelliteinstabilityhighsolidtumoursanopenlabelsinglearmmulticentrephaseiitrial AT zhangtao correctiontoserplulimabanovelantipd1antibodyinpatientswithmicrosatelliteinstabilityhighsolidtumoursanopenlabelsinglearmmulticentrephaseiitrial AT zhanghongyu correctiontoserplulimabanovelantipd1antibodyinpatientswithmicrosatelliteinstabilityhighsolidtumoursanopenlabelsinglearmmulticentrephaseiitrial AT wangxicheng correctiontoserplulimabanovelantipd1antibodyinpatientswithmicrosatelliteinstabilityhighsolidtumoursanopenlabelsinglearmmulticentrephaseiitrial AT wangwei correctiontoserplulimabanovelantipd1antibodyinpatientswithmicrosatelliteinstabilityhighsolidtumoursanopenlabelsinglearmmulticentrephaseiitrial AT hanlin correctiontoserplulimabanovelantipd1antibodyinpatientswithmicrosatelliteinstabilityhighsolidtumoursanopenlabelsinglearmmulticentrephaseiitrial AT wangqingyu correctiontoserplulimabanovelantipd1antibodyinpatientswithmicrosatelliteinstabilityhighsolidtumoursanopenlabelsinglearmmulticentrephaseiitrial AT zhujun correctiontoserplulimabanovelantipd1antibodyinpatientswithmicrosatelliteinstabilityhighsolidtumoursanopenlabelsinglearmmulticentrephaseiitrial AT correctiontoserplulimabanovelantipd1antibodyinpatientswithmicrosatelliteinstabilityhighsolidtumoursanopenlabelsinglearmmulticentrephaseiitrial |